| abstract |
Compositions comprising a TL1 A-Ig fusion protein and methods for their use for the treatment of, for example, diseases and disorders associated with antigen-specific immune responses are described. Also described is a combination therapy comprising administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and / or an mTOR inhibitor (e.g., rapamycin). (A) a first polypeptide comprising a polypeptide sequence that specifically binds to a tumor necrosis factor receptor superfamily, member 25 (TNFRSF25), and (b) an immunoglobulin (Ig) polypeptide A polynucleotide sequence encoding a fusion protein comprising a second polypeptide; Or a recombinant or isolated nucleic acid comprising a complementary polynucleotide thereof is provided herein. |